Uncategorized

Innovent Biologics, Inc. announces the licensing deal expansion with Synaffix B.V., a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates with best-in-class therapeutic index.

Ipsen, a global specialty-driven biopharmaceutical company, holds its Capital Markets Day in London, U.K.

ZyVersa Therapeutics, Inc. announced the pricing of a “reasonable best efforts” public offering of 4,000,000 shares of common stock and accompanying Series A and Series B warrants to purchase up to an aggregate of 8,000,000 shares of common stock at a combined public offering price of $1.25, resulting in gross proceeds of approximately $5.0 million.

The Phase 3 IMROZ trial evaluating the investigational use of Sarclisa® in combination with standard-of-care bortezomib, lenalidomide and dexamethasone met its primary endpoint at a planned interim analysis for efficacy, demonstrating statistically significant improvement in progression-free survival compared with VRd alone in transplant-ineligible patients with newly diagnosed multiple myeloma.

Spago Nanomedical AB announced that the first cancer patient has successfully been dosed in the clinical phase I/IIa study Tumorad-01 with the candidate drug 177Lu-SN201.

Carina Clingman, founder of The Collaboratory Career Hub, answers questions about the ins and outs of finding, landing and succeeding in openings in biotech.

The beleaguered insurer will leave the accountable care program at the end of the 2023 performance year following disappointing results in Medicare direct contracting.

The Baird survey of 38 health system CFOs forecasts that hospital capital spending growth in 2024 will slow from a 13% jump this year.

The company and claimants in Georgia filed to dismiss cases related to Ethicon’s Physiomesh in late November. 

The name change comes nearly two years after the merger between the health systems closed.